Completed
Phase II Capecitabine, Oxaliplatin & Bevacizumab for Metastatic / Unresectable Neuroendocrine Tumors
NCT00398320
- Conditions
- Neoplasms, Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, +3 more
- Locations
-
- Stanford University School of Medicine Stanford, California, United States